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simultaneous type I and type II photosensitization
for selective photodynamic cancer therapy†
Yen-Chih Lai and Cheng-Chung Chang*
We introduce a new class of photostable, eﬃcient photosensitizers based on boron-dipyrromethene
(BODIPY) derivatives that can generate singlet oxygen and superoxide simultaneously under irradiation.
First, we report the synthesis and design of how to control the generation of a speciﬁcally substituted
position of BODIPY. Second, after biologically evaluating the uptake, localization and phototoxicity in cell
lines, we conclude that 2,6-di-anisole substituted BODIPY is a potentially selective photodynamic
therapy candidate because its photodamage is more eﬃcient in cancer cells than in normal cells without
signiﬁcant dark toxicity.1. Introduction
Photodynamic therapy (PDT) involves the uptake of a photo-
sensitizer by cancerous tissues or other sites of the therapeutic
target, followed by selective irradiation with visible or near IR
light of an appropriate wavelength that is absorbed by the
photosensitizer. There are three fundamental requirements for
PDT that are oxygen, a light source, and a photosensitizer. Each
factor is harmless by itself, but their combination can produce
cytotoxic agents.1–3 There are many reported or commercially
available photosensitizers. By comparison, cyclic tetrapyrroles
(porphyrins, chlorins, and bacteriochlorins) are diﬃcult to
synthesize and modify; while phenothiazinium-based struc-
tures might be made more easily but present low light-to-dark
toxicity ratios.4–6 Most photosensitizers present application
limitations, such as a low photostability, structural instability,
or usable range of solvent conditions.7 Thus, it is important to
develop a new generation of photosensitizers with high eﬃ-
ciency and photostability that are widely applicable in various
conditions.
Selective photodamage is the most important criterion for
a superior PDT reagent. The eﬃcient delivery of a photo-
sensitizer to cancer cells and its subcellular distribution not
only depend on cellular processes but also on the physico-
chemical properties and structural characteristics of the
molecule itself.8 Therefore, several strategies have been
developed to improve the selective delivery of sensitizers to
tumour tissues, including their conjugation to carrierg, National Chung Hsing University, 250
ROC. E-mail: ccchang555@dragon.nchu.
n (ESI) available: Synthesis and
10.1039/c3tb21547d
–1583proteins,9 oligonucleotides,10 monoclonal antibodies,11
epidermal growth factors,12 carbohydrates,13 and hydrophilic
polymers.14 However, these high molecular weight branched-
peptide conjugates are diﬃcult to synthesize, purify, and
characterize. Although enhanced cellular uptake and selec-
tivity for tumour tissues have been achieved with some
porphyrin sensitizers, most of these are usually found in
cytoplasmic membranes rather than in sensitive intracellular
sites, such as the mitochondria, the endoplasmic reticulum
(ER), and the nuclei.
BODIPY (boron-dipyrromethene) derivatives oﬀer large
absorption extinction coeﬃcients, sharp uorescence emis-
sions with high uorescence quantum yields, photostability
and low sensitivity to environmental variation.15 Thus, BODIPY
derivatives have attracted much research interest and have been
used for many applications.16 The new application of BODIPY
derivatives for photosensitizers was achieved by attaching a
functional group which can oﬀer electrons to stabilize that
photoexcited BODIPY core and to quench the emission from the
singlet state, thereby promoting a triplet state lifetime.17
Specically, heavy atoms are incorporated into the structure as a
strategy to facilitate intersystem crossing and to promote the
singlet oxygen yield to become a new generation of photosen-
sitizers for photodynamic therapy.18,19 This appears to satisfy
the required criteria for a good photosensitizer (high singlet
oxygen yield, photostability and long wavelength absorption);
however, this approach disobeys the principle of dark-non-
toxicity for a photosensitizer to be a PDT candidate.20 More
importantly, based on the above considerations, it is rare to nd
BODIPY-based photosensitizers which present selective photo-
damage to cancer but not normal cells or tissues. Hence, it is
possible to design and produce, with appropriate chemical
modication, a new generation of BODIPY-based photosensi-
tizers that can overcome the issues of dark-toxicity andThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinenonselective photodamage without losing their unique optical
characteristics.
In this study, we report a novel photosensitizer that is highly
eﬃcient, photostable, and more importantly, showed selective
PDT behaviour. This strategy can be easily achieved by attaching
an aryl group directly onto the pyrrole moiety of BODIPY, but
this is not more expensive than dimethyl pyrrole. By controlling
the bromination sequence, 3,5- or 2,6-diaryl substituted BOD-
IPY derivatives can be collected with good yield. Preliminary
biological studies on one of these dyes indicate that this type of
compound is highly membrane permeable, and it can selec-
tively localize within specic subcellular organelles, suggesting
promising PDT applications for these molecules.2. Experimental
2.1 Materials
The general chemicals employed in this study were the highest
grade available and were obtained from Acros Organic Co.,
Merck Ltd., or Aldrich Chemical Co. and used without further
purication. All of the solvents were of spectrometric grade.2.2 Apparatus
The absorption spectra were generated using a Thermo Genesys
6 UV-visible spectrophotometer, and the uorescence spectra
were recorded using a HORIBA JOBIN-YVON Fluoromas-4
spectrouorometer with a 1 nm band-pass and a 1 cm cell
length at room temperature. The cellular uorescence images
and dual staining uorescence images were obtained using a
Leica AF6000 uorescencemicroscope with a DFC310 FX Digital
colour camera and a Leica TCS SP5 confocal uorescence
microscope. Fluorescence photographs were taken through the
related wavelength ranges using photomultiplier tubes (PMT).
The light source used to measure the singlet oxygen yield and
PDT cell death was a Xenon Light Source LAX-Cute (Asahi
Spectra).2.3 Cell culture conditions and compound incubation
Human embryonal lung MRC-5 normal broblast cells and
HeLa human cervical cancer cells were maintained in Modied
Eagle's Medium (MEM) containing non-essential amino acids,
Earle's salts, L-glutamine, 1 mM sodium bicarbonate, 1 mM
sodium pyruvate, 1% (penicillin + streptomycin) and 10% fetal
bovine serum (FBS); the human lung adenocarcinoma cell line
A549 was maintained in RPMI-1640 medium containing 1%
(penicillin + streptomycin), sodium bicarbonate (2.0 g L1) and
10% FBS. The cells were cultured at 37 C in a humid atmo-
sphere with 95% air and 5% CO2. Before the observation of
cellular localization, cells were seeded onto coverslips and
incubated for 24 h. The next day, cells were incubated with
diﬀerent concentrations of compounds for 12 h, for which the
DMSO stock solutions were diluted in serum-free medium
before use (1/100 v/v).This journal is © The Royal Society of Chemistry 20142.4 Light-induced cytotoxicity assay
Three diﬀerent cell types were examined in the assay: the
human lung MRC-5 normal cells, lung A549 cancer cells and
human cervical HeLa cancer cells. Varying concentrations of
compounds were incubated with the cells in the dark for 12 h.
Subsequently, the culture medium was removed, and fresh
culture medium was added to each well. The plates were irra-
diated using a light source that is described in the next section
and then incubated for a further 24 h at 37 C. All assay
experiments were carried out in triplicate, and an average of the
three individual runs are presented. Methylene blue and Foscan
were used as comparative standard controls and were assayed
according to previously documented procedures.21
2.5 Extraction and quantication of compounds in cells
HeLa cells (2  106) were seeded into 60 mm  15 mm cell
culture dishes. Before the cells reached 100% conuence, a
compound was added to one dish and incubated for 12 h. For
the dishes that were nearly 100% conuent, the conjugate
solution was added and incubated from 15 min to 4 h. Aer
incubation with the conjugates, all dishes were washed with
PBS. The cells were removed from the substrate with trypsin and
then pelleted. The cell suspension was sonicated for 1 h, and
1.8 mL of ethyl acetate was added to each tube to extract the
compound. Both absorbance and uorescence in the organic
phase were recorded.
2.6 Measurement
The light source for the measurement of singlet oxygen yield
and PDT cell death was a white light (a 20 W xenon lamp that
passes through a 400–700 nm mirror module). Before the light
was output from the optional light guide and collimator lens,
the light passed through a 510 nm long pass (lp) lter (the light
power was 6 mW cm2 on the dish surface). The singlet oxygen
quantum yields from compounds that were in an organic
solvent were determined by a photo-steady-state method using
1,3-diphenylisobenzofuran (DPBF) as the scavenger. Finally, the
following equation was utilized to calculate the singlet oxygen
quantum yields (FD):
FD ¼ [(n/nMB)  (AMB/A)]  FD,MB
where n is the DPBF oxidation rate, A, the area of absorbance
maxima of the compound and MB means methylene blue. The
value of singlet oxygen quantum yield (FD) for MB is 0.52 in
several media and measured with diﬀerent techniques.22,23 The
superoxide generation from compounds that were in an
aqueous solution was determined by a photo-steady-state
method using 4-((9-acridinecarbonyl)amino)-2,2,6,6-tetramethyl-
piperidin-1-oxyl (TEMPO-9-ac, Invitrogen, Carlsbad, CA) as the
radical detector. Dual staining of tracker and compound: the cells
were rst incubated with a compound for 12 h, which was fol-
lowed by incubation with 5 mM organelle probes (Mito Tracker
Green FM for 20 min at 37 C, ER Tracker™ Green for 30 min at
37 C), and then washed with PBS before observation. The exci-
tation source was a green light cube, in which the light passedJ. Mater. Chem. B, 2014, 2, 1576–1583 | 1577
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View Article Onlinethrough a 535 25 nmband pass (bp)lter and the emission was
collected through a 590 nm long pass (lp) lter (red emission of
compound) and a blue light cube, in which light passed through
a 470 20 nm bp lter and the emission was collected through a
510 nm lp lter to collect green emission of probes. Once the
denite yellow color image was presented, we said that the
compound was co-localized with the probes. PDT-induced
phototoxicity was determined using Hoechst 33342 (H-1399,
Invitrogen, USA) and propidium iodide (PI, P3566, Invitrogen,
USA) under a uorescencemicroscope and conrmed by a trypan
blue exclusion and staining assay. Determination of quantum
yields is relative to Rhodamine B.243. Results and discussion
3.1 Molecular preparation and basic spectroscopic
properties
BODIPY derivatives 2,6-DAB and 3,5-DAB were synthesized by
following diﬀerent routes as outlined in Scheme 1. Bromination
is the key reaction of molecule preparation in this study. The
8-(4-methoxyphenyl) boron-dipyrromethane, an intermediate
precursor of compound 2,6-A, was obtained upon BF3$Et2OScheme 1 Synthetic route to BODIPY-based photosensitizers 2,6-
DAB and 3,5-DAB: (i) pyrrole, TFA, rt. (ii) NBS, THF, ice bath. (iii) DDQ,
THF, rt. then Et3N–BF3$OEt2, toluene, reﬂux. (iv) K2CO3, (o-tol)3P,
Pd(OAc)2, DME/H2O ¼ 5/1, compound 2, reﬂux. (v) Pd(PPh3)2Cl2,
pinacolborane, dioxane/Et3N, reﬂux.
1578 | J. Mater. Chem. B, 2014, 2, 1576–1583complexation of compound 1. Then, the 2,6-dibromo
substituted BODIPY can be prepared by treating one equivalent
of 8-(4-methoxyphenyl) boron-dipyrromethane with 2.2 equiva-
lents of N-bromosuccinimide (NBS). Alternatively, when
compound 1 was brominated with NBS rst, the main product
was 3,5-dibromo substituted dipyrromethane, which is unstable
because it is easily protonated, especially in the column ush-
ing purication process. That is why we prepared compound
3,5-A in a sequence of steps in a one pot reaction directly from
compound 1 to 3,5-A. Notably, the use of 2.2 equivalents of NBS
provided dibromo-BODIPY in good yield along with a minor
amount of mono-substituted bromine. Here we claim that even
with an excess amount of the brominating agent, no regioiso-
meric products, such as 3,5-dibromo-substituted product in
2,6-A or 2,6-dibromo-substituted product in 3,5-A, were detected
in the reactions. Additionally, in the last step, compounds 2,6-A
and 3,5-A were both coupled with compound 2 with similar
yield in the same reaction conditions. Recently, most literature
presented the molecular constructions of unitary 3,5- or
2,6-disubstituted BODIPY were based on dimethylpyrrole
coupling with the Wittig reaction. Here we want to emphasize
that we can collect the 3,5-disubstituted and 2,6-disubstituted
BODIPY products, by using pyrrole as the starting material
instead of more expensive dimethylpyrrole. This breakthrough
result can be widely applied to organic synthesis.
In this investigation, the BODIPY moiety was selected as the
electron acceptor and anisole was chosen as the electron-
donating unit. The basic spectral properties in Fig. 1 show that
no signicant solvent polarity-dependent spectral shis in the
absorption and emission spectra were observed for the two
compounds 2,6-DAB and 3,5-DAB. However, when comparing
the spectral properties of these chromophores, 2,6-disubsti-
tuted product 2,6-DAB showed lower transition energy in all
investigated solvents with broader peak patterns in absorption
or emission spectra. Meanwhile, higher extinction coeﬃcient
values but lower quantum yields were obtained. This nding
indicates that, in the ground states, these chromophores are
signicantly stabilized by solvation and the auxiliary electron-
donating ability of anisole units oﬀered better eﬀectiveFig. 1 Absorption (left) and emission (right) spectra of compound
2,6-DAB (left) and 3,5-DAB (right) in diﬀerent solvents; characterized
by extinction coeﬃcient and quantum yield, respectively. Excited
wavelengths are depicted as absorption maxima.
This journal is © The Royal Society of Chemistry 2014
Fig. 2 Absorption spectra variations of 20 mM DPBF consumption in
the presence of 10 mM (a) 2,6-DAB and (b) 3,5-DAB in DMSO after
irradiation with an average 6 mW cm2 for the 510 nm lp through the
ﬁlter. Relative DPBF oxidation rates by singlet oxygen, which were
generated from the compounds, are plotted in (c); the data without the
510 nm lp ﬁlter are also shown. Each data point represents the average
from three separate experiments. (Inset: (a) control DPBF without
adding a compound, (b) identical experimental condition but with
methylene blue (MB).)
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View Article Onlineconjugation to the BODIPY core. However, 3,5-disubstituted
product compound 3,5-DAB exhibited more stable absorption
and luminescence properties in most organic solvents, espe-
cially with quantum yields ranging from 0.4 to 0.6. Based on our
knowledge, uorophores that can be successfully applied were
based on a single type of uorophore structure, common to all
integrated sensor molecules. The uorescent optical property of
3,5-DAB makes this proposal possible once we design and
synthesize derivatives with suitable spacers or functional
groups, so that it becomes 3,5-dialkoxyphenyl substituted
BODIPY, which will be applied in optical sensors, non-doped
OLEDS, or laser dyes. Furthermore, we expect that this type of
uorophore will be useful as a cellular probe because of its
unique optical property.
3.2 Singlet oxygen generation and photostability
The singlet-oxygen production study was undertaken by moni-
toring the reaction of the known singlet oxygen acceptor 1,3-
diphenylisobenzofuran (DPBF) with photosensitizer-generated
singlet oxygen.25 This production was achieved experimentally
by following the disappearance of the 410 nm absorbance band
of DPBF at an initial concentration of 20 mM (2 fold the
concentration of the compound). The rates of DPBF oxidation
by these two compounds in DMSO solvent were investigated by
exciting the absorptions of the compounds (Fig. 2). When
placed under the white light source (400–700 nm, no lter) or
visible light source (400–700 nm with a 510 nm long pass lter)
for the irradiation period, compound 2,6-DAB presented a
slightly better DPBF oxidation rate than compound 3,5-DAB.
Based on the result of Fig. 2, the estimated singlet oxygen yields
were about equal to the level of methylene blue (MB). Here, as
described in the Experimental, the singlet oxygen quantum
yields (FD) of compound 2,6-DAB and 3,5-DAB were obtained as
0.48 and 0.53 by the relative method using methylene blue as
the reference (FD ¼ 0.52). However, the singlet oxygen genera-
tions apparently increase when the system was irradiated under
a white light source. This nding indicates that the S0–S2
transition absorption bands of the compound at approximately
400 nm contribute some singlet oxygen yield. Additionally, the
inset in Fig. 2b shows that under this irradiation condition, the
photostabilities of compounds are better than MB. It is known
that good photostability upon repetitive excitation is highly
desirable in PDT application because photobleaching of
photosensitizers usually produces photodegradation side
products that may lower the eﬃciency of reactive oxygen species
(ROS) generation. Moreover, when a photosensitizer is used as a
tumour-visualizing tool in PDT, high photostability is required
to allow monitoring for a suﬃciently long period.26
3.3 Real-time photodamage and photostability in cells
Once these two compounds presented the characteristic
behaviours of singlet oxygen generation and photostability, we
examined whether the compounds can be used as a tool for cell
photosensitization. Fig. 3 illustrates the photodamage process
from a real-time video recorded under a uorescence micro-
scope with a colour CCD. This distinction was revealed by theThis journal is © The Royal Society of Chemistry 2014system measured uorescence using a 535  25 nm band pass
lter as an exciting light source and collected through a red
lter (590 nm long pass). It is clear that plasma membrane bleb
formation and acute cell death were caused by illumination
with green light for cells that were incubated with a compound.
Here, irradiated time dependent uorescent images show
nearly constant emission intensities, which further conrms
the photostability behaviour in Fig. 2; these two compounds
both cause apparent photodamage to cancer cells, but only
compound 2,6-DAB presents little or no collateral damage to
normal cells. Here, the important message is that in our studied
system, 2,6-disubstituted BODIPY (2,6-DAB) possibly shows
selective PDT to cancer cells rather than 3,5-disubstituted
BODIPY (3,5-DAB), even in unclear uorescent images becauseJ. Mater. Chem. B, 2014, 2, 1576–1583 | 1579
Fig. 3 Several selected ﬂuorescent and bright-ﬁeld photodamage
images from a real-time video of (a and c) HeLa cancer cells, and (b
and d) MRC-5 normal cells incubated with 10 mM 2,6-DAB (a and b) or
3,5-DAB (c and d) for 12 h after 535 25 nm irradiation from amercury
lamp for ﬂuorescent microscopy.
Fig. 4 Intracellular accumulations of 2,6-DAB (a) and 3,5-DAB (b) in
normal (MRC-5) and cancer (HeLa) cells. The cells were incubated with
variable concentrations of compounds for 12 h, and the intracellular
uptake was determined from a ﬂuorescence calibration curve of the
ethyl acetate layer after extracting from the cells. Each data point
represents the average from three separate experiments.
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View Article Onlineof low quantum yield. This result suggests that 2,6-DAB is a
potentially useful reagent for cell photosensitization, studies on
oxidative stress, or PDT.
3.4 Intracellular accumulation
Following the experimental conditions of Fig. 3, we tried to
determine the quantitative accumulation of compounds in the
cells using red (590 nm long pass) lters, as in Fig. S1.† The
compound 3,5-DAB presented clearer concentration-depen-
dent intracellular uorescent signals because of the com-
pound's higher emission quantum yield, and these
intracellular accumulation images appear no diﬀerent
between cancer cells and normal cells. The intracellular
accumulation of compound 2,6-DAB is diﬃcult to observe
because of its low uorescent quantum yield. Thus, the1580 | J. Mater. Chem. B, 2014, 2, 1576–1583kinetics of compound uptake was determined by the extrac-
tion of the compound from cells.27 By monitoring the absor-
bance and uorescence intensities of compounds in the ethyl
acetate layer aer extracting from the cells, as in the Experi-
mental section description, the increase in the compound
concentration in the cells was quantied (Fig. 4). It is clearly
conrmed that the cellular uptake of 3,5-DAB appears no
diﬀerent between cancer and normal cells, whereas 2,6-DAB
accumulated in the cancer cells more than in the normal cells.
This notable observation supports us to propose that the
uptake diﬀerence between cancer and normal cells is the
dominant factor for selective photodamage.3.5 Sub-cellular localization
It is known that the intracellular localization of photosensi-
tizers strongly aﬀects the mechanism of cell death. The bio-
logical eﬃcacy for most photodynamic therapy (PDT)
sensitizers of tumors depends on their eﬃcient translocation
across cellular membranes and their delivery into specic
organelles within cancer cells.28 To determine the localization of
each compound, as detailed in the Experimental section, the
cells incubated with compound 2,6-DAB were double stained
with cellular tracker green, which merged with the red light
emission region of the compound. Fig. 5 reveals that 2,6-DAB isThis journal is © The Royal Society of Chemistry 2014
Fig. 5 Sub-cellular localization of 2,6-DAB in HeLa cancer cells: the
images of tracker green were excited by a blue light cube that passed
light through a 470  20 nm bp ﬁlter, and emission was collected
through a 510 nm lp ﬁlter. The red images of the compound were
excited by a green light cube that passed light through a 535  25 nm
bp ﬁlter, and emission was collected through a 590 nm lp ﬁlter.
Fig. 6 Phototoxicity of cells treated with variable concentrations of
2,6-DAB for 12 h before irradiation and irradiated with a 510 nm lp light
source (average 8 J cm2); cell death was tested overnight. Each data
point represents the average from three separate experiments and the
irradiation condition details are described in the Experimental section.
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View Article Onlinelocalized predominantly in the endoplasmic reticulum (ER) and
less in the mitochondria of cancer cells.
Generally, mitochondrial photodamage has been reported to
be the primary cause of apoptosis during PDT because the
mitochondria play an integral role in various cell biological
processes, such as energy production, apoptotic cell death,
molecular metabolism, calcium signaling, and cell redox
status.29–31 However, ER is also a very attractive site for the
localization of the photosensitizers to improve the eﬃciency of
PDT. It is known that oxidation of ER proteins due to PDT may
cause changes in ER Ca2+ homeostasis and/or aggregation of
unfolded and misfolded proteins.32 For example, the ER-local-
izing photosensitizer Foscan was recently shown to cause Bcl-2
photodamage, possibly specically aﬀecting the ER pool of Bcl-
2 in cancer cells.33,34 Based on the literature, PDT with photo-
sensitizers that target mitochondria and ER will very possibly
cause photodamage to Bcl-2 and Bcl-Xl,35 and this type of pho-
todamage to these antiapoptotic proteins is observed immedi-
ately upon light exposure,36 as in Fig. 3. It is doubtless that the
ability of PDT to aﬀect Bcl-2 function plays a crucial role in
tumour treatment.3.6 Phototoxicity
The combination of compound 2,6-DAB and light illumination
resulted in quantitative cellular toxicity. Fig. 6 reveals that three
diﬀerent cell lines displayed no determinable dark toxicity with
2,6-DAB up to a concentration of 15 mM. By contrast, irradiation
with 8 J cm2 of 510 nm long pass light dose showed a signif-
icant light-induced toxicity with EC50 values determined for
HeLa, A549, and MRC-5 as 5.7, 8.2 and 18.5 mM, respectively. A
more apparent phototoxicity result was observed when the
system was irradiated under white light (400–700 nm) as the
PDT light source. On the other hand, an interesting result was
observed when the cell death was determined with double
staining Hoechst 33342 as well as PI.37,38 Fig. S2† shows that in
the early stage of cell death (two probes stained once immedi-
ately aer illuminating), uorescent images result in apparentThis journal is © The Royal Society of Chemistry 2014blue emission enhancement in the nucleus. This result is
because of the interaction between Hoechst and condensed
DNA. This occurred when the red uorescence from PI became
dominant in the nucleus when the irradiated cell line was
cultured overnight. It is likely that the nuclear membrane is
damaged during a later period aer irradiation. This cell death
pathway is likely because of an anti-apoptosis protein of mito-
chondria or ER, as discussed above. However, we provided an
additional PDT reagent as another choice, and this is the rst
report for a BODIPY derivative to show selective PDT to cancer
cells but not normal cells.3.7 New reactive oxygen species generation
It is notable that the PDT eﬀects of 2,6-DAB are better than we
expected. Hence, we examined the possibility for this com-
pound's PDT progress by other possible mechanisms, such as
type I PDT. The type I mechanism involves hydrogen-atom
abstraction or electron-transfer between the excited sensitizer
and a substrate, yielding free radicals. These radicals can
react with oxygen to form an active oxygen species, such as the
superoxide radical anion.39,40 Most studies generally infer
that singlet oxygen formation of type II PDT is primarily
responsible for the biological PDT eﬀect; however, several
recent studies indicate that radical species from the type I
mechanismmay lead to an amplied PDT response, particularly
under low oxygen conditions.41,42 It is reported that these two
competing mechanisms can occur simultaneously.28,43 The free
radical probe 4-((9-acridinecarbonyl)amino)-2,2,6,6-tetramethyl-
piperidin-1-oxyl (TEMPO-9-ac, Invitrogen, Carlsbad, CA) captures
radicals, resulting in uorescence turn-on (lex/em ¼ 358/
440 nm).44 Irradiation of 2,6-DAB also generated a more apparent
increase in signal from TEMPO-9-ac compared to unchanged
levels of the control (Fig. 7). This nding indicates that
compound 2,6-DAB may undergo type I and II PDTJ. Mater. Chem. B, 2014, 2, 1576–1583 | 1581
Fig. 7 (a) Absorption spectra of TEMPO-9ac upon irradiation with
compound 2,6-DAB. Experimental conditions follow Fig. 2. Emission
(lex ¼ 360 nm) spectra of TEMPO-9ac upon irradiation without
compound (b) and with compound 2,6-DAB (c).
Journal of Materials Chemistry B Paper
Pu
bl
ish
ed
 o
n 
20
 D
ec
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
by
 N
at
io
na
l C
hu
ng
 H
sin
g 
U
ni
ve
rs
ity
 o
n 
23
/0
3/
20
14
 1
4:
47
:1
3.
 
View Article Onlinesimultaneously when it stays in the cells. We proposed that is why
the PDT eﬀects of 2,6-DAB are better than we expected.4. Conclusions
BODIPY oﬀers many superior optical properties. In this study,
we have successfully applied BODIPY derivatives for cancer
targeting and demonstrated that the 2,6-di-anisole substituted
product 2,6-DABmay be a potent tumor-specic photosensitizer
for PDT. First, we presented a cheap and convenient synthesis
procedure that can be widely applied to prepare diversied
BODIPY derivatives. Second, ROS generation as well as biolog-
ical evolution of cellular uptake, localization and phototoxicity
was determined. Therefore, the PDT characteristics of the
2,6-DAB compound include (1) target selectivity for the PDT of
cancer cells; (2) higher photostability than methylene blue; (3)
supported extra phototoxicity with superoxide generation.Acknowledgements
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